Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 18 of the 23 references it cites were found in a registry or an index.
Abstract
This study, a subgroup analysis of the data from the Organization Program of DiabEtes INsulIN ManaGement study, aimed to compare the efficacy and safety profiles of acarbose and metformin used in combination with premixed insulin.This analysis included 80 and 192 patients taking only 1 oral antidiabetic drug, classified into acarbose (treated with acarbose + insulin) and metformin groups (treated with metformin + insulin), respectively. The efficacy and safety data were analyzed for within- and between-group differences. The clinical trial registry number was NCT01338376.The percentage of patients who achieved target hemoglobin A1c (HbA1c) <7% in the acarbose and metformin groups were 38.75% and 30.73%, respectively, after a 16-week treatment. The average HbA1c levels in the acarbose and metformin groups were comparable at baseline and decreased significantly in both groups at the end of the study. All 7 blood glucose decreased significantly in both groups at endpoint compared with that at baseline. Insulin consumption was higher in the metformin group in terms of total daily amount and units/kg body weight. Incidences of hypoglycemia were similar in both groups. Body weight changed significantly in both groups from baseline to endpoint, but with no significant difference between the groups. Mean scores of Morisky Medication Adherence Scale improved in both groups at endpoint.Combination of insulin with acarbose or metformin could improve glycemic control in patients with type 2 diabetes mellitus. Acarbose and metformin were found to be comparable in terms of efficacy, weight gain, and incidence of hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In persons with T2D being treated with alpha-glucosidase inhibitors, who develop hypoglycemia due to use of hypoglycemic agents, oral glucose or lactose-containing foods (dairy products) must be given because alpha-glucosidase inhibitors inhibit the breakdown and absorption of complex carbohydrates and disaccharides.1218–1225”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1218]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Diagnosis and Classification of diabetes mellitus
(2014) · Diapedia · doi:10.14496/dia..20 · Cited by 3,214
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031 · cited 1×
“7% in 2007–08, making China mainland the country with the largest diabetes prevalence in the world.([1]) Despite the high prevalence of diabetes, China faces challenges in managing the disease because of low level of awareness, low treatment rate, and even lower controlling rate with regard to diabetes.”
BackgroundSelf-citationThe Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
Causes of type 2 diabetes in China
Ronald, C. W., Xu, L., & Jia, W. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70145-7 · Cited by 173
Yang, W., Liu, J., Shan, Z., Tian, H., Zhou, Z., Ji, Q., Weng, J., Jia, W., Lu, J., Liu, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70021-4 · Cited by 163 · cited 3×
“The Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment (MARCH) study([7]) was the first one that directly compared the safety and efficacy profiles of metformin or acarbose treatment in patients with newly diagnosed T2DM in China.”
BackgroundResultSelf-citationGu, S., Shi, J., Tang, Z., Sawhney, M., Hu, H., Shi, L., Fonseca, V., & Dong, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126704 · Cited by 61 · cited 1×
“Moreover, Gu et al([18]) performed a meta-analysis in 2015 to compare the glucose-lowering effect of metformin and acarbose in T2DM.”
MethodLi, S., Xiao, J., Ji, L., Weng, J., Jia, W., Lu, J., Zhou, Z., Guo, X., Liu, J., Shan, Z., et al. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.03.015 · Cited by 60 · cited 9×
“Acarbose is now used as the preferred drug for some patients with newly diagnosed T2DM.([5,13,14]) Acarbose competitively inhibits the a-glycosidase on the surface of epithelial cells from the duodenum and small intestine, delays the metabolism and assimilation of carbohydrates, and thus effectively decreases PBG as w…”
BackgroundResultSelf-citation中华医学会糖尿病学分会 (2014) · Chin J Diabetes Mellitus · doi:10.3760/cma.j.issn.1674-5809.2014.07.004 · Cited by 50
C hina type 2 diabetes treatment status survey of treatment pattern of oral drugs users
Ji, L., Lu, J., Weng, J., Jia, W., Tian, H., Zhu, D., Xing, X., & Guo, L. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12165 · Cited by 49
Research works printed but not linked: 1
- Lu, 2012, Glycaemic control in patients with type 2 diabetes treated with oral antidiabetic drugs in urban areas of China, Chin J Diabetes Mellitus, 4, 402
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Sintsova, O. V., Gladkikh, I. N., Kalinovskii, A. P., Zelepuga, E., Monastyrnaya, M., Kim, N., Шевченко, Л. С., Peigneur, S., Tytgat, J., Kozlovskaya, E. P., et al. (2019) · Marine Drugs · doi:10.3390/md17100542 · Cited by 27
Pan, R., Lou, J., & Wei, L. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10252 · Cited by 28
Gao, F., Ma, X., Peng, J., Lu, J., Lu, W., Zhu, W., Bao, Y., Vigersky, R. A., Jia, W., & Zhou, J. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0290 · Cited by 24
Aoki, K., Sato, H., & Terauchi, Y. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0041 · Cited by 23
Metadata
- Authors
- Wu, H., Liu, J., Lou, Q., Liu, J., Shen, L., Zhang, M., Lv, X., Gu, M., & Guo, X.
- Affiliations
- Sir Run Run Shaw Hospital (CN)
- Gansu Provincial Hospital (CN)
- Peking University First Hospital (CN)
- Peking University People's Hospital (CN)
- Chinese PLA General Hospital (CN)
- Shanghai Pudong New Area Gongli Hospital (CN)
- Corresponding author
- Guo, Xiaohui
- Venue
- Medicine
- Published
- 2017-09
- Volume
- 96
- Issue
- 35
- Pages
- e7533
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC5585474
- OpenAlex
- W2751273963
- Cited by
- 17
- References
- 23
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 4 · 2018: 2
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nd
- Locations
- Medicine (publishedVersion, cc-by-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nd)
- PubMed Central (publishedVersion, cc-by-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- acarbose, metformin, premixed insulin, type 2 diabetes, glycemic control, HbA1c, hypoglycemia, insulin dose, body weight, medication adherence, oral antidiabetic drugs, insulin therapy
- MeSH terms
- Administration, Oral, Blood Glucose, China, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Metformin, Middle Aged, Treatment Outcome, Acarbose, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1097/md.0000000000007533
- The paper
- Wu, H., Liu, J., Lou, Q., Liu, J., Shen, L., Zhang, M., Lv, X., Gu, M., & Guo, X. (2017). Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus. Medicine. https://doi.org/10.1097/md.0000000000007533
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.